Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

被引：35

作者：

Awad, Mark M. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 08期

关键词：

SARCOMATOID CARCINOMA; AMPLIFICATION; CRIZOTINIB; GEFITINIB; PATIENT; CBL; UBIQUITINATION; RESPONSIVENESS; CHEMOTHERAPY; SENSITIVITY;

D O I：

10.1200/JCO.2015.64.2777

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：879 / +

页数：5

共 48 条

[21] Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies [J].

Makishima, Hideki ;

Cazzolli, Heather ;

Szpurka, Hadrian ;

Dunbar, Andrew ;

Tiu, Ramon ;

Huh, Jungwon ;

Muramatsu, Hideki ;

O'Keefe, Christine ;

Hsi, Eric ;

Paquette, Ronald L. ;

Kojima, Seiji ;

List, Alan F. ;

Sekeres, Mikkael A. ;

McDevitt, Michael A. ;

Maciejewski, Jaroslaw P. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6109-6116

[22] MET-Mutated NSCLC with Major Response to Crizotinib [J].

Mendenhall, Melody A. ;

Goldman, Jonathan W. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :E33-E34

[23] Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers [J].

Onozato, Ryoichi ;

Kosaka, Takayuki ;

Kuwano, Hiroyuki ;

Sekido, Yoshitaka ;

Yatabe, Yasushi ;

Mitsudomi, Tetsuya .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) :5-11

[24] Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification [J].

Ou, Sai-Hong Ignatius ;

Kwak, Eunice L. ;

Siwak-Tapp, Christina ;

Dy, Joni ;

Bergethon, Kristin ;

Clark, Jeffrey W. ;

Camidge, D. Ross ;

Solomon, Benjamin J. ;

Maki, Robert G. ;

Bang, Yung-Jue ;

Kim, Dong-Wan ;

Christensen, James ;

Tan, Weiwei ;

Wilner, Keith D. ;

Salgia, Ravi ;

Iafrate, A. John .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) :942-946

[25] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[26] Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping [J].

Paik, Paul K. ;

Drilon, Alexander ;

Fan, Pang-Dian ;

Yu, Helena ;

Rekhtman, Natasha ;

Ginsberg, Michelle S. ;

Borsu, Laetitia ;

Schultz, Nikolaus ;

Berger, Michael F. ;

Rudin, Charles M. ;

Ladanyi, Marc .

CANCER DISCOVERY, 2015, 5 (08) :842-849

[27] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[28] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) [J].

Paz-Ares, Luis ;

Horn, Leora ;

Borghaei, Hossein ;

Spigel, David R. ;

Steins, Martin ;

Ready, Neal ;

Chow, Laura Quan Man ;

Vokes, Everett E. ;

Felip, Enriqueta ;

Holgado, Esther ;

Barlesi, Fabrice ;

Kohlhaeufl, Martin ;

Rodriguez, Oscar ;

Burgio, Marco Angelo ;

Fayette, Jerome ;

Gettinger, Scott N. ;

Harbison, Christopher ;

Dorange, Cecile ;

Finckenstein, Friedrich Graf ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)

[29] From Tpr-Met to Met, tumorigenesis and tubes [J].

Peschard, P. ;

Park, M. .

ONCOGENE, 2007, 26 (09) :1276-1285

[30] Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein [J].

Peschard, P ;

Fournier, TM ;

Lamorte, L ;

Naujokas, MA ;

Band, H ;

Langdon, WY ;

Park, M .

MOLECULAR CELL, 2001, 8 (05) :995-1004

← 1 2 3 4 5 →